Day One Biopharmaceuticals (DAWN) Price & Analysis

Compare

351 Followers

DAWN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.64 - $16.76

Previous CloseN/A

Volume175.11K

Average Volume (3M)1.69M

Market Cap

$754.92M

Enterprise Value$219.85M

Total Cash (Recent Filing)$453.10M

Total Debt (Recent Filing)$3.00M

Price to Earnings (P/E)―

Beta1.55

Next Earnings

Nov 10, 2025

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding102,431,930

10 Day Avg. Volume957,477

30 Day Avg. Volume1,693,750

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.29

Enterprise Value/Revenue1.17

Enterprise Value/Gross Profit1.25

Enterprise Value/Ebitda-2.00

Forecast

1Y Price Target

$23.25

Price Target Upside215.47% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Market PositionOjemda's favorable rash profile reinforces its front-line potential, with over 95% of dermatologic events being low grade and rarely requiring dose modification.

Product AdoptionOjemda launch continues to expand on depth of patients per prescriber, with 60% of accounts now having multiple patients, and 20% with 5+, setting up for optimal growth.

Strategic ExecutionStrategic pipeline execution and capital allocation reinforce a growth-oriented, de-risked oncology platform, with ongoing advancements in precision oncology.

Bears Say

Financial PerformanceThe 2Q25 EPS of -$0.29, while slightly higher than consensus, reflects a challenging financial performance.

Revenue GuidanceThe FY 2025 product net revenue guidance of $140M - $150M is lower than the consensus of $151.7M.

Sales PerformanceOjemda sales of $33.9M came in approximately 4.5% lower than consensus expectations.

Day One Biopharmaceuticals News

Day One Biopharmaceuticals initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Day One Biopharmaceuticals (DAWN) with an Overweight rating and $25 price target Piper...

26d ago

DAWN

Day One Biopharmaceuticals initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Day One Biopharmaceuticals (DAWN) with an Overweight rating and $25 price target Published...

26d ago

DAWN

Promising Growth and Stability Drive Buy Rating for Day One Biopharmaceuticals

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on DAWN stock, giving a Buy rating on...

1M ago

DAWN

Day One Biopharma’s Earnings Call Highlights Growth and Strategy

Day One Biopharmaceuticals, Inc. (($DAWN)) has held its Q2 earnings call. Read on for the main highlights of...

1M ago

DAWN

Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Day One Biopharmaceuticals and decreased the...

1M ago

DAWN

Buy Rating for Day One Biopharmaceuticals Amid Promising Future Catalysts Despite Current Challenges

Day One Biopharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia...

1M ago

DAWN

Day One Biopharmaceuticals price target lowered to $17 from $20 at BofA

BofA lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $17 from $20 and keeps a...

1M ago

DAWN

Day One price target lowered to $25 from $36 at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $25 from...

1M ago

DAWN

Day One Biopharma Reports Strong Q2 2025 Growth

Day One Biopharmaceuticals, Inc. ( ($DAWN) ) has released its Q2 earnings. Here is a breakdown of the...

1M ago

DAWN

Day One Biopharmaceuticals Reports Strong Q2 2025 Results

Day One Biopharmaceuticals ( ($DAWN) ) just unveiled an update. On August 5, 2025, Day One Biopharmaceuticals reported...

1M ago

DAWN

Day One Biopharmaceuticals reports Q2 EPS (29c), consensus (34c)

Reports Q2 revenue $33.91M, consensus $34.9M. “We have strong momentum going into the second half of 2025. We...

1M ago

DAWN

Day One Biopharmaceuticals appoints Michael Vasconcelles as Head of R&D

Day One Biopharmaceuticals (DAWN) announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research &...

3M ago

DAWN

Day One Biopharmaceuticals Approves Key Proposals at Annual Meeting

Day One Biopharmaceuticals ( ($DAWN) ) just unveiled an announcement. On June 2, 2025, Day One Biopharmaceuticals held...

3M ago

DAWN

Positive Outlook for Day One Biopharmaceuticals’ Ojemda: A Promising First-Line Treatment for Pediatric Glioma

Analyst Soumit Roy of JonesTrading maintained a Buy rating on Day One Biopharmaceuticals (DAWN – Research Report), retaining...

3M ago

DAWN

DAWN FAQ

What was Day One Biopharmaceuticals’s price range in the past 12 months?

Day One Biopharmaceuticals lowest stock price was $5.63 and its highest was $16.76 in the past 12 months.

What is Day One Biopharmaceuticals’s market cap?

Day One Biopharmaceuticals’s market cap is $754.92M.

When is Day One Biopharmaceuticals’s upcoming earnings report date?

Day One Biopharmaceuticals’s upcoming earnings report date is Nov 10, 2025 which is in 57 days.

How were Day One Biopharmaceuticals’s earnings last quarter?

Day One Biopharmaceuticals released its earnings results on Aug 05, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.357 by $0.067.

Is Day One Biopharmaceuticals overvalued?

According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Day One Biopharmaceuticals pay dividends?

Day One Biopharmaceuticals does not currently pay dividends.

What is Day One Biopharmaceuticals’s EPS estimate?

Day One Biopharmaceuticals’s EPS estimate is -0.29.

How many shares outstanding does Day One Biopharmaceuticals have?

Day One Biopharmaceuticals has 102,431,930 shares outstanding.

What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?

Day One Biopharmaceuticals reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.357. Following the earnings report the stock price went down -15.698%.

Which hedge fund is a major shareholder of Day One Biopharmaceuticals?

Currently, no hedge funds are holding shares in DAWN

Day One Biopharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

-24.75%

Trailing 12-Months

Asset Growth

29.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Day One Biopharmaceuticals (DAWN) Earnings & Revenues

Historic Earnings Reports

DAWN Company Deck

DAWN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a strong positive sentiment with significant achievements in revenue growth, prescription numbers, and financial stability. The momentum of OJEMDA's launch and the promising pipeline developments outweighed the single noted lowlight of discontinuing the VRK1 program.View all DAWN earnings summaries

DAWN Stock 12 Month Forecast

Average Price Target

$23.25

▲(215.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","35":"$35","12.5":"$12.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.5,20,27.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,8.753846153846155,10.857692307692307,12.961538461538462,15.065384615384616,17.169230769230772,19.27307692307692,21.376923076923077,23.480769230769234,25.584615384615383,27.68846153846154,29.792307692307695,31.896153846153844,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,7.926923076923077,9.203846153846154,10.480769230769232,11.75769230769231,13.034615384615385,14.311538461538463,15.588461538461539,16.865384615384617,18.142307692307696,19.419230769230772,20.696153846153848,21.973076923076924,{"y":23.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,7.36923076923077,8.088461538461539,8.807692307692308,9.526923076923078,10.246153846153847,10.965384615384615,11.684615384615384,12.403846153846153,13.123076923076923,13.842307692307692,14.561538461538461,15.28076923076923,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.17,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.84,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >